TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31651050

Group type: EXPERIMENTAL
Intervention: Heel subjected to pressure on mattress
Number of subjects: 18

Group type: COMPARATOR
Intervention: Heel protected by pillow
Number of subjects: 18
Study: 31651098

Group type: EXPERIMENTAL
Intervention: Long-acting injectable PrEP
Number of subjects: 136
Study: 31651278

Group type: EXPERIMENTAL
Intervention: Anemia Etiology in Ethiopia (AnemEE) survey
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulated interventions (e.g., iron fortification)
Number of subjects: 0
Study: 31651359

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenous infusion every 2 weeks (1 L subgroup)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenous infusion every 2 weeks (2 L subgroup)
Number of subjects: 82
Study: 31651364

Group type: EXPERIMENTAL
Intervention: Standardized oral care bundle (oral assessment, tooth brushing, moisturization, and secretion removal)
Number of subjects: 4200

Group type: COMPARATOR
Intervention: Oral chlorhexidine
Number of subjects: 4200
Study: 31651363

Group type: EXPERIMENTAL
Intervention: NY-ESO-1 SPEAR T cells with fludarabine-containing conditioning regimen
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Fludarabine-containing conditioning regimen
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: NY-ESO-1 SPEAR T cells
Number of subjects: 42
Study: 31651951

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant (OAC) use
Number of subjects: 15092

Group type: EXPERIMENTAL
Intervention: Non-vitamin K antagonist oral anticoagulants (NOACs) use
Number of subjects: 15092

Group type: EXPERIMENTAL
Intervention: Antiplatelet monotherapy
Number of subjects: 15092

Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 15092

Group type: EXPERIMENTAL
Intervention: OAC use in patients aged 65-74, 75-84, and ≥85 years with high bleeding risk (HAS-BLED ≥3)
Number of subjects: 15092

Group type: EXPERIMENTAL
Intervention: Antiplatelet only in patients aged 65-74, 75-84, and ≥85 years with high bleeding risk (HAS-BLED ≥3)
Number of subjects: 15092

Group type: EXPERIMENTAL
Intervention: OAC use in patients ≥85 years by region
Number of subjects: 15092
Study: 31651956

Group type: EXPERIMENTAL
Intervention: Machine learning classifiers (specifically XGBoost) for imputation of self-harm events
Number of subjects: 10120030

Group type: COMPARATOR
Intervention: Coded self-harm events
Number of subjects: 10120030

Group type: EXPERIMENTAL
Intervention: Imputed self-harm events
Number of subjects: 10120030

Group type: EXPERIMENTAL
Intervention: Machine learning features used for classification
Number of subjects: 10120030

Group type: EXPERIMENTAL
Intervention: Self-harm undercoding in males vs females
Number of subjects: 10120030

Group type: EXPERIMENTAL
Intervention: Self-harm undercoding in seniors
Number of subjects: 10120030
Study: 31652009

Group type: EXPERIMENTAL
Intervention: Oral iron supplementation starting at 65 mg daily, titrated based on fasting serum iron concentration.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral iron supplementation
Number of subjects: 6
Study: 31652392

Group type: EXPERIMENTAL
Intervention: SOF/VEL (sofosbuvir/velpatasvir) pretransplant and on posttransplant Day 1 (Group 1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SOF/VEL (sofosbuvir/velpatasvir) on Days 2 and 3 posttransplant (Group 2A and Group 2B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 4-day SOF/VEL strategy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Posttransplant DAA therapy for viremic patients
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall patient and allograft survivals
Number of subjects: 50
Study: 31652401

Group type: EXPERIMENTAL
Intervention: Longitudinal study examining leukocyte telomere length (LTL) in children and their parents
Number of subjects: 0
Study: 31652765

Group type: EXPERIMENTAL
Intervention: Systematic Physical Exercise
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study: 31652997

Group type: EXPERIMENTAL
Intervention: RC28-E (5 mg/kg, 15 mg/kg, and 50 mg/kg, ip. Tiw × 9)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mono-target antagonist treatment (VEGF or FGF blocking)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RC28-E
Number of subjects: 0
Study: 31653207

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) measurements taken at ED presentation
Number of subjects: 1084

Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) measurements taken at ED presentation
Number of subjects: 1084
Study: 31653352

Group type: EXPERIMENTAL
Intervention: Interatrial shunt device (IASD) implantation
Number of subjects: 64
Study: 31653796

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided L5 dorsal ramus block using a pivot technique
Number of subjects: 100
Study: 31654156

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 100
Study: 31654272

Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg/day (initial alemtuzumab treatment; IAT) for 5 days initially, then 3 days 12 months later
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (pooled IAT/DAT)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (IAT only)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Subcutaneous interferon beta-1a (SC IFNB-1a) 3×/week (control)
Number of subjects: 43
Study: 31654285

Group type: EXPERIMENTAL
Intervention: Everolimus 5 mg PO daily and panobinostat 10 mg PO 3 times weekly (weeks 1 and 2) given in 21-day cycles
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Everolimus/panobinostat therapy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: miR-605 levels
Number of subjects: 21
Study: 31654541

Group type: EXPERIMENTAL
Intervention: High angiogenic tumor (HAT)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Low angiogenic tumor (LAT)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Infiltrated peripheral edema (IPE)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Vasogenic peripheral edema (VPE)
Number of subjects: 184
Study: 31655045

Group type: EXPERIMENTAL
Intervention: GSEED-RE model
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: ACER model
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: GSEED-RE2 model
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Overall prediction models (GSEED-RE and ACER)
Number of subjects: 1034

Group type: COMPARATOR
Intervention: Factors associated with delayed bleeding
Number of subjects: 1034
Study: 31655222

Group type: EXPERIMENTAL
Intervention: ACVR1 (R206H) mutation in individuals with FOP
Number of subjects: 113
Study: 31655936

Group type: EXPERIMENTAL
Intervention: telotristat ethyl treatment
Number of subjects: 135
Study: 31656217

Group type: EXPERIMENTAL
Intervention: Enhanced ERN in children with high BI
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Blunted ERN in children with high childhood irritability
Number of subjects: 291
Study: 31448107

Group type: EXPERIMENTAL
Intervention: Home-Based Exercise after Total Hip Arthroplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31656630

Group type: EXPERIMENTAL
Intervention: Autologous fat grafting to the affected area of skin
Number of subjects: 1
Study: 31656987

Group type: EXPERIMENTAL
Intervention: Decongestive lymphatic therapy (DLT)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Patient-borne costs
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Indirect costs borne by patients
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Society-borne costs
Number of subjects: 8
Study: 31657082

Group type: EXPERIMENTAL
Intervention: Glucocorticoids (GC) treatment for 7 days in GC-resistant patients (n=7)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Glucocorticoids (GC) treatment
Number of subjects: 49
Study: 31657503

Group type: EXPERIMENTAL
Intervention: Vineland-3
Number of subjects: 106
Study: 31657648

Group type: EXPERIMENTAL
Intervention: Fibroblast Growth Factor Receptor Inhibitors
Number of subjects: 0
Study: 31657964

Group type: EXPERIMENTAL
Intervention: 10% increase in step rate using an audible metronome during a single session of gait retraining
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study: 31658128

Group type: EXPERIMENTAL
Intervention: Endoscopic Sleeve Gastroplasty (ESG)
Number of subjects: 109
Study: 31658475

Group type: COMPARATOR
Intervention: Unguided biopsy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Arthroscopically guided biopsy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All cases (combined results)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Revision surgery
Number of subjects: 40
Study: 31659543

Group type: EXPERIMENTAL
Intervention: CT coronary angiography (CTA)
Number of subjects: 150
Study: 31659631

Group type: EXPERIMENTAL
Intervention: Authors' predictive model using CK19 mRNA and CEUS score
Number of subjects: 235

Group type: COMPARATOR
Intervention: MSKCC nomogram
Number of subjects: 235
Study: 31659739

Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy (AT)
Number of subjects: 136
Study: 31659847

Group type: EXPERIMENTAL
Intervention: Epidural steroid injection (ESI)
Number of subjects: 11
Study: 31659915

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MR-proANP
Number of subjects: 0
Study: 31660391

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (maintained serum 25(OH)D >30 ng/mL)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 31660640

Group type: EXPERIMENTAL
Intervention: Tofacitinib de-escalation (from 10 mg b.d. to 5 mg b.d.)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Tofacitinib escalation (from 5 mg b.d. to 10 mg b.d.)
Number of subjects: 123
Study: 31660903

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy followed by total mesorectal excision
Number of subjects: 84
Study: 31660992

Group type: EXPERIMENTAL
Intervention: Curative surgery for rectal adenocarcinoma
Number of subjects: 188
Study: 31661079

Group type: EXPERIMENTAL
Intervention: Continuous vital sign monitoring with alerts sent to nursing staff
Number of subjects: 2049

Group type: EXPERIMENTAL
Intervention: eHealth technology for patient monitoring
Number of subjects: 2049
Study: 31661339

Group type: EXPERIMENTAL
Intervention: CLAM (Cladribine + AraC + Mitoxantrone)
Number of subjects: 253

Group type: COMPARATOR
Intervention: DAC (Daunorubicin + AraC + Cladribine)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: DAC reinduction
Number of subjects: 253

Group type: COMPARATOR
Intervention: Not receiving CLAM
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 253
Study: 31661530

Group type: EXPERIMENTAL
Intervention: Skhokho intervention, details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 31661690

Group type: EXPERIMENTAL
Intervention: CEUS_C
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CEUS_B
Number of subjects: 30
Study: 31662377

Group type: EXPERIMENTAL
Intervention: MD Anderson Symptom Inventory-Lung Cancer Module (MDASI-LC) for symptom data collection preoperatively, daily postoperatively during in-hospital stay, and weekly after discharge until 4 weeks or start of postoperative oncological therapy.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: MD Anderson Symptom Inventory-Lung Cancer Module (MDASI-LC) interference-measured functional status as an anchor for alert thresholds.
Number of subjects: 300
Study: 31662404

Group type: EXPERIMENTAL
Intervention: T-MACS decision aid algorithm with point-of-care troponin assays
Number of subjects: 0
Study: 31662412

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (12 mg/d IV; 5 days at baseline, 3 days 12 months later)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (as-needed or other disease-modifying therapy in a 4-year extension)
Number of subjects: 0
Study: 31662765

Group type: EXPERIMENTAL
Intervention: Gelatin scaffold with hMSSM-derived cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collagen scaffold with hMSSM-derived cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite/tricalcium phosphate (HA) scaffold with hMSSM-derived cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (fibrin/thrombin scaffold with hMSSM-derived cells)
Number of subjects: 0
Study: 31662801

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide extended release (TA-ER) 32 mg into each knee (total 64 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional triamcinolone acetonide crystalline suspension (TAcs) 40 mg into each knee (total 80 mg)
Number of subjects: 0
Study: 31662874

Group type: EXPERIMENTAL
Intervention: Simvastatin and Ezetimibe
Number of subjects: 1136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1136
Study: 31662893

Group type: EXPERIMENTAL
Intervention: Transepithelial AXL
Number of subjects: 20

Group type: COMPARATOR
Intervention: Epithelium-off AXL
Number of subjects: 20
Study: 31663247

Group type: EXPERIMENTAL
Intervention: Patients with POH (cases)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Patients without POH (controls)
Number of subjects: 303
Study: 31663410

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sedentary behavior
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31663465

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg + methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abatacept + methotrexate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sarilumab + methotrexate
Number of subjects: 0
Study: 31663906

Group type: EXPERIMENTAL
Intervention: Wireless motility capsules (WMC)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Gastric emptying scintigraphy (GES)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both tests (WMC and GES)
Number of subjects: 150
Study: 31664603

Group type: EXPERIMENTAL
Intervention: Young patients (18 to 54 years)
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Middle-aged patients (55 to 67 years)
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Elderly patients (67 years and older)
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator (biomarker of coagulation)
Number of subjects: 618
Study: 31664941

Group type: EXPERIMENTAL
Intervention: High prenatal maternal stress (scores >5)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Moderate prenatal maternal stress (scores 3-5)
Number of subjects: 353
Study: 31664962

Group type: EXPERIMENTAL
Intervention: PD-L1 expression ≥50%
Number of subjects: 154

Group type: COMPARATOR
Intervention: PD-L1 expression <50%
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: BRAF mutation positive
Number of subjects: 154

Group type: COMPARATOR
Intervention: BRAF mutation negative
Number of subjects: 154
Study: 31665006

Group type: EXPERIMENTAL
Intervention: Post-stroke activity limitations evaluated by the modified Rankin score
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cognitive disorders assessed by standardized and validated scales
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Anxio-depressive disorders assessed by standardized and validated scales
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fatigue assessed by standardized and validated scales
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Restriction of participation assessed by standardized and validated scales
Number of subjects: 100
Study: 31665021

Group type: EXPERIMENTAL
Intervention: I-FFQ
Number of subjects: 137
Study: 31665061

Group type: EXPERIMENTAL
Intervention: Chest compressions during CPR
Number of subjects: 30
Study: 31665141

Group type: EXPERIMENTAL
Intervention: Heat-stable toxin-based vaccine candidates, dosage and duration not specified
Number of subjects: 0
Study: 31665349

Group type: EXPERIMENTAL
Intervention: Graded IV glucose infusion
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Arginine administration
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (nonexposed)
Number of subjects: 32
Study: 31665380

Group type: EXPERIMENTAL
Intervention: Ceramide-18 (Cer-18)
Number of subjects: 2337

Group type: EXPERIMENTAL
Intervention: Ceramide-20 (Cer-20)
Number of subjects: 2337

Group type: EXPERIMENTAL
Intervention: Ceramide-22 (Cer-22)
Number of subjects: 2337

Group type: EXPERIMENTAL
Intervention: Ceramide-24 (Cer-24)
Number of subjects: 2337

Group type: EXPERIMENTAL
Intervention: Ceramide-16 (Cer-16)
Number of subjects: 2337

Group type: EXPERIMENTAL
Intervention: Sphingomyelins (SMs)
Number of subjects: 2337

Group type: EXPERIMENTAL
Intervention: Glucosyl-ceramides
Number of subjects: 2337

Group type: EXPERIMENTAL
Intervention: Lactosyl-ceramide
Number of subjects: 2337
Study: 31665480

Group type: COMPARATOR
Intervention: hGIP1-42 infusion during fasting glycemia
Number of subjects: 22

Group type: COMPARATOR
Intervention: hGIP1-42 infusion during hyperglycemic clamping
Number of subjects: 22

Group type: COMPARATOR
Intervention: hGIP1-42 infusion during insulin-induced hypoglycemia
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: pGIP1-42 infusion in isolated porcine pancreata
Number of subjects: 22
Study: 31665959

Group type: EXPERIMENTAL
Intervention: DBP 30 to <60 mm Hg
Number of subjects: 2897

Group type: EXPERIMENTAL
Intervention: SBP 90 to <120 mm Hg
Number of subjects: 2897

Group type: EXPERIMENTAL
Intervention: Lower SBP (<120 mm Hg)
Number of subjects: 2897

Group type: EXPERIMENTAL
Intervention: Lower DBP (<60 mm Hg)
Number of subjects: 2897
Study: 31666040

Group type: EXPERIMENTAL
Intervention: Personal motivation to lose weight
Number of subjects: 3008

Group type: EXPERIMENTAL
Intervention: Willingness to talk to a diabetes educator about weight
Number of subjects: 3008

Group type: EXPERIMENTAL
Intervention: Weight loss attempts recognized by a healthcare provider
Number of subjects: 3008

Group type: EXPERIMENTAL
Intervention: Diagnosis of 'obesity' or 'overweight'
Number of subjects: 3008
Study: 31666061

Group type: EXPERIMENTAL
Intervention: Routine infection-prevention methods in the ED
Number of subjects: 446

Group type: COMPARATOR
Intervention: Routine infection-prevention methods in the GW
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: High-risk individuals in the ED
Number of subjects: 446

Group type: COMPARATOR
Intervention: High-risk individuals in the GW
Number of subjects: 446

Group type: COMPARATOR
Intervention: Attack rate of MERS in the GW
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Attack rate of MERS in the ED
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Transmission in intermediate- and low-risk groups in the ED
Number of subjects: 446

Group type: COMPARATOR
Intervention: Transmission in low-risk group in the GW
Number of subjects: 446
Study: 31666082

Group type: EXPERIMENTAL
Intervention: Subcutaneous EEG
Number of subjects: 4

Group type: COMPARATOR
Intervention: Long-term video scalp EEG (LTV EEG)
Number of subjects: 4
Study: 31666237

Group type: EXPERIMENTAL
Intervention: naproxen 750 mg immediately then 250 mg every 8 hours for 7 days
Number of subjects: 399

Group type: COMPARATOR
Intervention: low-dose colchicine 500 mcg three times per day for 4 days
Number of subjects: 399
Study: 31666276

Group type: COMPARATOR
Intervention: Screening for HLH in 16 ICUs, diagnosis based on HLH-2004 criteria and expert review.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Exploration of a panel of potential biomarker candidates.
Number of subjects: 100
Study: 31667609

Group type: EXPERIMENTAL
Intervention: Second trimester serum lipids
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Third trimester serum lipids
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Comparison of serum lipids from second to third trimester
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Effect of prematurity on serum lipids
Number of subjects: 748
Study: 31667659

Group type: EXPERIMENTAL
Intervention: Olaparib (100 mg bid) + Carboplatin (AUC 4)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Olaparib + Carboplatin + Paclitaxel
Number of subjects: 57
Study: 31667696

Group type: EXPERIMENTAL
Intervention: Conventional-dose oseltamivir (75 mg for adolescents/adults; 30-75 mg by body weight for children), twice daily for 10 days
Number of subjects: 228

Group type: COMPARATOR
Intervention: Double-dose oseltamivir (150 mg for adolescents/adults; 60-150 mg for children), twice daily for 10 days
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Conventional-dose oseltamivir
Number of subjects: 228

Group type: COMPARATOR
Intervention: Double-dose oseltamivir
Number of subjects: 228
Study: 31668140

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 31668348

Group type: EXPERIMENTAL
Intervention: Iron deficiency (ferritin <100 μg L)
Number of subjects: 730
Study: 31668380

Group type: EXPERIMENTAL
Intervention: Conventional culture
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Rapid molecular test (Xpert® SA Nasal Complete)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Attempt to decolonise
Number of subjects: 200
Study: 31668516

Group type: EXPERIMENTAL
Intervention: Patient decision aid for medication treatment for opioid use disorder (PtDA-MOUD)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (matched controls who did not receive the PtDA)
Number of subjects: 36
Study: 31668571

Group type: EXPERIMENTAL
Intervention: FAINT score of 0
Number of subjects: 3177

Group type: EXPERIMENTAL
Intervention: FAINT score greater than or equal to 1
Number of subjects: 3177

Group type: EXPERIMENTAL
Intervention: FAINT score
Number of subjects: 3177

Group type: EXPERIMENTAL
Intervention: 30-day all-cause mortality or serious cardiac outcome
Number of subjects: 3177
Study: 31668633

Group type: EXPERIMENTAL
Intervention: Urine PLIN-2 assay
Number of subjects: 0

Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with bladder cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with diabetic nephropathy
Number of subjects: 0
Study: 31668646

Group type: EXPERIMENTAL
Intervention: rTMS on the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Functional connectivity (FC) of sgACC to right DLPFC and rACC to left lateral parietal cortex (IPL)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Longitudinal rs-fMRI data analyses
Number of subjects: 50
Study: 31668825

Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA) administered prior to induction and prior to post-remission therapy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA) measures pre- and post-induction
Number of subjects: 43